Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991270 | 0.86 | CHRNB2 (0.39) | CHRNB2CHRNA4SIGMAR1NUDT1MAPK14 | |
| SCHEMBL10142489 | 0.78 | CHRNB2 (0.41) | CHRNB2CHRNA4SIGMAR1NUDT1IGF1R | |
| SCHEMBL2989851 | 0.78 | — | — | |
| SCHEMBL3091229 | 0.73 | CES1 (0.45) | — | |
| SCHEMBL2991527 | 0.72 | GABRG2 (0.35) | — | |
| SCHEMBL9923725 | 0.71 | NUDT1 (0.35) | NUDT1IGF1RCDK2DYRK1BPRKCI | |
| SCHEMBL22579806 | 0.70 | SIGMAR1 (0.48) | CHRNB2CHRNA4SIGMAR1ROCK2AAK1 | |
| SCHEMBL10599 | 0.69 | AAK1 (0.36) | NUDT1ROCK2AAK1 | |
| SCHEMBL7431568 | 0.68 | PDE3B (0.36) | CHRNB2CHRNA4SIGMAR1CDK2DYRK1B | |
| SCHEMBL9923726 | 0.68 | NUDT1 (0.32) | NUDT1MAPK14MAPTGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| CN-101068781-B | Compounds for alzheimer's disease | MYRIAD GENETICS, INC. (US) | 2012-02-01 | — | — | CN | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101460164-A | Compounds for diseases and disorders | MYRIAD GENETICS INC (US) | 2009-06-17 | — | — | CN | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2010187-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| CN-101068781-A | Compounds for alzheimer's disease | MYRIAD GENETICS INC (US) | 2007-11-07 | — | — | CN | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809601-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | CHRNB2 412/4885CHRNA4 1042/4885SIGMAR1 1191/4885 |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | CHRNB2 412/4885CHRNA4 1042/4885SIGMAR1 1191/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | CHRNB2 168/4885CHRNA4 303/4885SIGMAR1 2198/4885 |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | PSEN2, PSEN1, CLN6 | CHRNB2 174/4885CHRNA4 613/4885SIGMAR1 1875/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | CHRNB2 145/4885CHRNA4 499/4885SIGMAR1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.